In the Claims

Applicants have submitted a new complete claim set with insertions and deletions to the amended claims indicated by underlining and strikeouts, respectively.

Please amend pending claim 6 as noted below.

1-5. (Cancelled)

6. (Currently amended) An isolated protein encoded by an isolated nucleic acid molecule selected from the group consisting of:

(a) nucleic acid molecules which encode a cancer antigen that stimulates an immune response, and which comprise a nucleotide sequence, the complementary sequence of which hybridizes, under stringent conditions, to at least one second nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of the nucleotide sequences set forth as SEQ ID NOs: 1, 2, 3, 4, and 5,

(b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy of the genetic code, and

(c) full length complements of (a) or (b), wherein the stringent conditions are hybridization at 65°C in hybridization buffer (3.5x SSC, 1x Denhardt's solution; 25 mM sodium phosphate buffer (pH 7.0), followed by four washes (one hour, each wash , at 65°C., 2xSSC, 0.1% SDS), and a final wash for 30 minutes at 1.0xSSC 0.2% SDS ~~0.5% SDS, 2mM EDTA), wherein SSC is 0.15M sodium chloride/0.015M sodium citrate, pH7; wherein SDS is sodium dodecyl sulphate, and EDTA is ethylenediaminetetraacetic acid~~.

7-36. (Cancelled)

37. (Previously presented) A composition of matter useful in stimulating an immune response to at least one protein encoded by at least one nucleic acid molecule comprising a nucleotide sequence set forth in SEQ ID NO: 1, 2, 3, 4 or 5, said composition comprising a plurality of immunogenic peptides derived from the amino acid sequence of at least one of the said

proteins, wherein said peptides bind to one or more MHC molecules presented on the surface of cells.

38. (Original) The composition of matter of claim 37, wherein at least a portion of said plurality of peptides bind to MHC molecules and elicit a cytolytic response thereto.

39. (Original) The composition of matter of claim 38, further comprising an adjuvant.

40. (Original) The composition of matter of claim 39, wherein said adjuvant is a saponin, GM-CSF, or an interleukin.

41-56. (Cancelled)

57. (Previously presented) The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:1.

58. (Previously presented) The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:2.

59. (Previously presented) The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:3.

60. (Previously presented) The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:4.

61. (Previously presented) The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:5.

62. (Previously presented) The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:1.

63. (Previously presented) The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:2.

64. (Previously presented) The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:3.

65. (Previously presented) The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:4.

66. (Previously presented) The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:5.

67. (Previously presented) The composition of matter of claim 37, wherein at least one of the plurality of peptides is coupled to an immune response stimulating compound.